BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics
Current Blockbusters, New Products To Make Up Difference
Executive Summary
Bristol executives reiterated the company’s aggressive revenue growth expectations while outlining the impact Revlimid generics will have in Europe, Japan and – to a limited extent – in the US.
You may also be interested in...
Q4 Earnings Preview: It's All About Growth Goals And Deal Plans (Part 2)
Industry's big players report fourth quarter results over the next two weeks. Updates on leadership changes, growth targets and deal plans are among the hot topics.
Cipla Remains Upbeat On Abraxane As US Generic Competition Looms
Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.
Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.